再投30亿美元！礼来宣布扩建，GLP-1产能再获提升

Medaverse12-06

12月5日，印第安纳波利斯，礼来公司（NYSE:LLY）宣布斥资30亿美元扩建该公司今年早些时候收购的威斯康星州基诺沙县生产制造工厂。这项投资将扩大礼来的全球注射产品生产制造网络，帮助满足其糖尿病、肥胖症和未来治疗领域对管线药物日益增长的需求。礼来预计将在该工厂现有的100多名员工基础上增加750个高技能岗位。（替尔泊肽头对头打败司美格鲁肽，平均减重20.2%对13.7%）礼来计划明年开始扩建工程...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2489001478?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-06 12:57","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2489001478","market":"us","top_or_hot":-1,"title":"再投30亿美元！礼来宣布扩建，GLP-1产能再获提升","media":"Medaverse","content":"<div>\n<p>12月5日，印第安纳波利斯，礼来公司（NYSE:LLY）宣布斥资30亿美元扩建该公司今年早些时候收购的威斯康星州基诺沙县生产制造工厂。这项投资将扩大礼来的全球注射产品生产制造网络，帮助满足其糖尿病、肥胖症和未来治疗领域对管线药物日益增长的需求。礼来预计将在该工厂现有的100多名员工基础上增加750个高技能岗位。（替尔泊肽头对头打败司美格鲁肽，平均减重20.2%对13.7%）礼来计划明年开始扩建工程...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206130054a1d83d33&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再投30亿美元！礼来宣布扩建，GLP-1产能再获提升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再投30亿美元！礼来宣布扩建，GLP-1产能再获提升\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 12:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206130054a1d83d33&s=b><strong>Medaverse</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月5日，印第安纳波利斯，礼来公司（NYSE:LLY）宣布斥资30亿美元扩建该公司今年早些时候收购的威斯康星州基诺沙县生产制造工厂。这项投资将扩大礼来的全球注射产品生产制造网络，帮助满足其糖尿病、肥胖症和未来治疗领域对管线药物日益增长的需求。礼来预计将在该工厂现有的100多名员工基础上增加750个高技能岗位。（替尔泊肽头对头打败司美格鲁肽，平均减重20.2%对13.7%）礼来计划明年开始扩建工程...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206130054a1d83d33&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1868836914.USD","symbol_name":"CT (LUX) I AMERICAN \"3\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206130054a1d83d33&s=b","article_id":"2489001478","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206130054a1d83d33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2489001478","pubTimestamp":1733461077,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"礼来预计将在该工厂现有的100多名员工基础上增加750个高技能岗位。自2020年以来，礼来公司已承诺投资230多亿美元在全球范围内建设、扩建和收购生产基地。今年9月礼来投资18亿美元扩大爱尔兰两家工厂的产能。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","GLP":"全球合伙","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LLY":"礼来","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4516":"特朗普概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU0882574139.USD":"富达环球消费行业基金A ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4534":"瑞士信贷持仓","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC"},"translate_title":"Invest another $3 billion! Eli Lilly announces expansion, GLP-1 production capacity is increased again","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1,"LLY":1},"content_text":"12月5日，印第安纳波利斯，礼来公司（NYSE:LLY）宣布斥资30亿美元扩建该公司今年早些时候收购的威斯康星州基诺沙县生产制造工厂。这项投资将扩大礼来的全球注射产品生产制造网络，帮助满足其糖尿病、肥胖症和未来治疗领域对管线药物日益增长的需求。礼来预计将在该工厂现有的100多名员工基础上增加750个高技能岗位。（替尔泊肽头对头打败司美格鲁肽，平均减重20.2%对13.7%）礼来计划明年开始扩建工程。这是礼来历史性的制造业扩张议程的又一步，旨在帮助更多依赖其药物的人。自2020年以来，礼来公司已承诺投资230多亿美元在全球范围内建设、扩建和收购生产基地。今年9月礼来投资18亿美元扩大爱尔兰两家工厂的产能。礼来还在德国阿尔泽市建造了一座价值25亿美元的工厂，预计将于2027年开始生产。10月，礼来透露将在印第安纳州的一家研发和制造工厂投资45亿美元，并将其命名为礼来制药铸造厂。已经承诺投资90亿美元在这个庞大的工厂建造一个活性药物成分工厂，该工厂将生产其注射式重磅糖尿病和肥胖症药物Mounjaro和Zepbound。此外，在北卡罗来纳州三角研究园区正在建设一座价值17亿美元的工厂，该公司预计将于2027年投入运营。礼来公司执行副总裁兼生产运营总裁Edgardo Hernandez表示：“今天的公告代表了我们在印第安纳州以外的最大一笔美国制造业投资，将增加我们在中西部扩大现有和未来药品生产线的能力。我们期待为威斯康星州的人们带来高薪、先进制造业、工程和科学工作，威斯康星州正成为我们全球制造业运营的关键地理位置。”收购、扩建和额外购买土地和相邻仓库使礼来公司在威斯康星州的计划总投资达到40亿美元。扩建后的工厂将专注于生产注射药物、设备组装和多个治疗领域的药物包装。礼来将使用先进的自动化技术，包括引导车、机器人和生产设备，以加快药品生产。从数据管理到运营，数字自动化将嵌入整个工厂，以加速流程并提高准确性，使员工能够专注于生产安全、高质量的药物。现场新的高技能工作将包括操作员、技术人员、工程师和科学家，此外还有扩建项目施工期间的2000多个建筑工作岗位。威斯康星州州长Tony Evers表示：“威斯康星州东南部在过去一年中实现了巨大的增长，各大公司宣布在我们州进行重大投资，我们很高兴礼来公司以30亿美元的扩张加入这一不断增长的名单，这将为基诺沙县增加750个高技能、家庭支持的工作岗位。作为美国区域技术中心，威斯康星州是个性化医疗和生物健康领域的领导者，通过与礼来公司的合作，我们将继续推进研究和创新，支持威斯康星州的制造业，同时支持我们州和世界各地的工人、家庭和患者。”礼来公司旨在通过与当地高等教育机构建立伙伴关系，支持威斯康星州的各种社区倡议，推进制药制造业的创新。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489001478"}